Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Is Being Restructured by A Reverse Merger

Part 1

April 20, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006

Part 2

April 21, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694

Part 3 Radient Is Being Restructured by A Reverse Merger

April 22, 2015

"The Company is currently insolvent and the new Board of Directors and the new senior management of the Company have been appointed to attempt to restructure the Company."

http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm

Facts to keep in mind from Part 1 and Part 2

1.) Why did Capital Venture International loan Radient 11 million dollars that included 36 investors after the announcement of CIT Phase II and Phase III to be be researched in India in a PR on April 8, 2010. The attorney who arranged the offering is a RTO (Reverse Merger) specialist and partner in the same law firm that represented Radient in 2011 (CIT Law Suit) and accepted 300,000 USD of services rendered for future payment of Radient stock at .01 per share/30 Million shares at 4 per cent annual interest to be converted on of after April 30, 2015.

2.)Why did Radient sign a 5 Year exclusive LPA in Novemebr 2010 to allow Provista Diagnostics to research, develop, and commercialize DR-70 to combine it with their Breast and Lung Cancer tests(Technology)which ends in November 2015. The same company that wanted to reverse merge with Radient.

3.) Why did one investor of Provista Diagnostics (David Reese) in 2011 decide that he along with other Angel investors wanted to take over Provista Diagnostics. In 2011, Provista Diagnostics Breast and Lung Cancer tests were owned by Provista Life Sciences and combined with Dr-70, Radients Technology.

4.)Why didn't Radient just end up in bankruptcy courts and end up "sweeter"as some have suggested instead of restructuring? The reason for restructuring and not bankruptcy ..The equity capital firms, Provista Diagnostic angel investors and a few remaining longs would be harmed.

5.) The most important fact. Who owns around 90 per cent of the 4.5 billion outstanding RXPC shares of 5 billion that was authorized? The answer..The equity capital firms, and the Provista Diagnostic angel investors.

6.) Which vehicle will Provista Diagnostics and its 35 angel investors utilize to go Public? The answer..The Radient shell.

Radient Is Being Restructured by A Reverse Merger

This is my Hypothesis presented with facts and my honest opinions you understand....

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Part 3

In my recent postings we mentioned that the agreement between Radient and Global Cancer Technology was completed because William had paid 6000 USD..We threw that out to get reaction..There was no reaction.. We stated in the past that the 6000 USD was used to reopen the patent pending of the new onko-sure. We still believe that is where the money came from to reopen the patent pending. We still believe the reopening of the patent pending was a smoke screen. Before my recent statement some stated in the past that there was not an agreement. We agree with those people. There was not an agreement. It was what we stated in the past, that it was just a smokescreen. The reason we took the same stand is because William sold PLS Breast and Lung cancer tests to Provista Diagnostics. Also if you look at the royalty schedule in the agreement it started on January 1, 2013. The agreement began on July 17, 2012 and was postponed several times because William was supposedly waiting for a 2 million dollar closing from the investors that bought PDX. The Uni-Pharma agreement on the other hand started on the day it was signed. Another reason the agreement was not signed is the time it has taken for the GCDX lung cancer to be marketed..The agreement if agreed meant William would have had to pay 400,000 dollars in 2013, 2014, and 2015. Not likely..Someone mentioned a few days ago that William was selling Dr-70 Lung cancer test. We can prove that argument is not valid or feasible. The ROC stated in his Video was 97% for men and 98% for women..Onko Sure/Dr-70 never had that high of a ROC on its own.In the PR in 2010 the "LC Sentinel" ROC was stated at 97%. On GCDX it was on his web site for months at 97% and was changed when I brought it up on the board that it had to be the "LC Sentinel" Lung Cancer test..It was immediately changed to 92%. It was also in the Arizona Biz article from 2013 at 97%..Therefore GCDX is selling the "LC Sentinel" lung cancer test..The poster was correct. William is selling DR-70, but William and GCDX are selling Dr-70 with Provista Diagnostic test that William sold to PDX..How can that happen? Because after the sale of the Breast and Lung cancer test to PDX is still an executive with Provista Diagnostics. It only makes sense that GCDX was set up as a future wholly owned subsidiary or a future division of PDX..Since William is selling "LC Sentinel" Radient is still involved with Provista Diagnostics.. There is no documentation that PDX sold their Lung cancer test they bought from William back to William..That is redicuous to ever imagine. Radient and Provista have a 5 year exclusive (LSA) to research, develop, and commercialize DR-70. GCDX and the Lung Cancer test is the first of those projects completed and now commercialized..The LSA is for the USA only. The agreement with Bertech in Canada appears to be a smokescreen in my opinion.

Here is the LSA once again..

Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has entered into an exclusive 5-year Laboratory Services Agreement (LSA) with Provista Diagnostics Inc. (Provista). Provista conducts diagnostic research and provides CLIA laboratory developed tests and services to the general public.

Under the terms of the LSA, Provista will have the exclusive rights in the U.S. to develop and market CLIA laboratory developed tests (LDTs) for cancer screening purposes using RPC's proprietary polyclonal antibodies for fibrin and fibrinogen degradation products (FDP).

According to Douglas MacLellan, Executive Chairman and CEO of Radient Pharmaceuticals, "Collaboration with Provista is a natural fit for us. They have a strong, long-standing reputation for providing state-of-the-art CLIA testing services. In forging this relationship, Radient will be securing a new laboratory services and testing distribution channel for its products and we are extremely excited to expand a relationship between our two firms."

The LSA provides for both minimum quarterly antibody purchases from RPC and for RPC to share in the net proceeds from the sale of any LDTs that are developed by Provista from RPC's proprietary FDP antibodies.

Provista CEO William Gartner commented, "We have already successfully brought one cancer screening test to the market called the BT Test, which is a highly accurate blood test for the detection of breast cancer in women. Under our agreement with RPC we will actively pursue the development of new cancer screening and detection assays using RPC's proprietary FDP antibodies." According to Gartner this also includes accelerating the market introduction of a very sensitive FDP-derived CLIA laboratory developed test for lung cancer screening.

RPC also offers its Onko-Sure® test kit; a simple non-invasive patent-pending and FDA approved in vitro diagnostic (IVD) test kit for colon-rectal cancer (CRC) recurrence monitoring. The test enables physicians and healthcare professionals to effectively monitor CRC by measuring the accumulation of FDP in the blood. FDP levels rise dramatically with the progression of this cancer.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence.



http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Announces-Exclusive-5-Year-Laboratory-Services-Agreement-With-NYSE-Amex-RPC-1345331.htm


"Gartner said he wasn’t bothered much by the lack of venture capital funding that occurred during the recession, preferring instead to work with equity capital firms, angel investors and family institutional investors."



In the article posted below and the quote above, William stated that he sold his BT Test(Breast Cancer Test) and his Lung Cancer test to Provista Diagnostics to a Group of equity capital firms, angel investors and family institutional investors. We know who the Angel investors and family institutional investors are, they are members of the Board of Directors at Provista Diagnostics. The unknown is the names of the Equity capital firms that are involved with the sale of PLS Breast and cancer tests to Provista Diagnostics.. The only place we could find from our research on any equity capital firms involved with the comment would be those found in the SEC filings of Radient.

"Recently, Gartner sold Phoenix-based Provista Life Sciences LLC’s breast and lung cancer testing technologies to a new company called Provista Diagnostics Inc., which he intends to take public by the middle of next year."

From the quote above and in the article below dated December 30, 2011, William stated he sold his breast and lung cancer tests to Provista Diagnostics and intends to take Provista Diagnostics public. The sale was in August 2011 when David Reese was appointed the CEO. Why did it take Provista Diagnostics 11 months(July 2012) to take "LC Sentinel" off their web site pipeline section? Some say it was because Provista Diagnostics dropped the Lung Cancer Test they bought from PLS/William Gartner all together. That is not true.."LC Sentinel"was a combination of Dr-70 and antibodies and biomarkers of the BT Test. The same test William sold to Provista Diagnostics. The reason it was dropped from their site is because Provista Diagnostics was branded as a Women's cancer company. "LC Sentinel" was later placed in Global cancer Diagnostics and would be run by William Gartner as a wholly owned subsidiary or Division in our opinion..

March 1, 2012 is when the first offering from 19 of the Provista Diagnostics angel and family institutional investors. There is no mention of any equity capital firms in Provista Diagnostic filings..In later offerings the angel investors increases to 35.There were 36 investors in the 2010 Radient offering to the equity capital firm, Capital Venture International.

http://www.sec.gov/Archives/edgar/data/1539252/000153925212000005/0001539252-12-000005-index.htm

http://www.sec.gov/Archives/edgar/data/1539252/000153925212000005/xslFormDX01/primary_doc.xml

On May 13, 2012 Global Cancer Diagnostics filed for a corporation in Arizona. It was approved on June 20, 2012 with William Gartner as the sole shareholder owner.It was on July 17, 2012 in a SEC 8-K filing by Radient announcing an agreement between Global Cancer Diagnostics and Radient.

http://starpas.azcc.gov/scripts/cgiip.exe/WService=wsbroker1/names-detail.p?name-id=17681354&type=CORPORATION

In July 2012 this SEC filing came out in connection with the "LC Sentinel" Lung Cancer test. GCDX was entering in an agreement with Radient for the use of DR-70 for a "Lung Cancer Test only..Why for a Lung Test only? Provista had the exclusive rights for the DR-70 for all Cancer tests, including the lung cancer test in the USA. It appears from our analysis that GCDX will be the International Division of Provista Diagnostics when the 2010 proposed reverse merger is finalized.

http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/0001144204-12-039787-index.htm



LICENSE AGREEMENT

This License Agreement (the "Agreement"), which shall be effective as of July 13, 2012, is by and between Global Cancer Diagnostics Inc., an Arizona corporation ("GCDx") and Radient Pharmaceuticals Corporation, a Delaware corporation ("RXPC"); and.

Whereas, the GCDx wishes to hold an exclusive global license to a blood test for lung cancer (the “LC Test”), procedures, analyses, data, manufacturing processes, components, trademarks and intellectual property identified in Exhibit A (the "Intellectual Property");

Whereas, RXPC desires to grant a license to GCDx to commercialize a Lung Cancer Test (the “LC Test”) into the global market;

Whereas, GCDx will not make, use of or sell any other RXPC test using the DR-70 reagents and will be the only company offering a test specific to lung cancer,

http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_ex10-1.htm

In Part 4, we will go more into detail about the facts and opinions we brought forth in Part 3 about the Radient, Provista Dx, and GCDX relationship concerning the GCDX/Radient agreement and the LSA between Radient and Provista Diagnostics.